An expert from The University of Texas MD Anderson Cancer Center offers advice on the best diet to enrich a patient’s microbiome and consequent immunotherapy response.
Experts discuss how, it is crucial to approach treatment strategies with both compassion and transparency. It is important to explain the complexity of the situation and maintain clear and accessible language when discussing treatment strategies with patients and their families.
Chevon Rariy, MD, outlines patient eligibility criteria, and the alterations to the nurse patient relationship, as CTCA launches the novel Oncology Clinic at Home Program.
Kristin E. Rojas, M.D., FACS, FACOG, assistant professor of surgical oncology in the DeWitt Daughtry Department of Surgery and Sylvester Comprehensive Cancer Center at the University Miami Miller School of Medicine, realized she had struck a chord with women being treated for cancer when she started the Menopause Urogenital Sexual Health and Intimacy Clinic (MUSIC).
Karolina Faysman, NP, explains how step-up dosing is used to reduce CRS and ICANS with bispecific antibodies in multiple myeloma.
A tiered level preceptor recognition program offers a cost-effective organizational intervention designed to acknowledge and incentivize the contributions of advanced practice preceptors.
Tia Wheatley, DNP, RN, AOCNS, BMTCN, and Shivani Gopalsami, RN, MSN, ANP-BC, AOCNP, discuss the benefits and challenges of multidisciplinary collaboration in hematopoietic stem cell transplant care.
Adding darolutamide to androgen deprivation therapy and docetaxel delayed the progression from metastatic hormone-sensitive prostate cancer to metastatic castration-resistant disease.
Panelists emphasize the importance of multidisciplinary collaboration, patient education, and advocacy in managing multiple myeloma while expressing optimism about emerging therapies like CAR T cells that offer deeper remissions and improved quality of life.
Janice Post-White, PhD, RN, FAAN, an oncology nurse and caregiver, discusses how she handled the guilt she felt following her son’s leukemia diagnosis.
Ranee Mehra, MD, discusses the link between PD-L1 expression and increased immunotherapy efficacy in head and neck squamous cell carcinoma, and what future treatment options may look like for patients in this space.
Advanced practice providers are the future of survivorship care because of the tremendous value they offer to the practice and its patients.
Martin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.
New AQUILA data show PFS improvement in patients with smoldering multiple myeloma who were treated with subcutaneous daratumumab vs active monitoring.
Panelists discuss how they approach long-term monitoring and follow-up care for patients who have ALK-positive+ patients disease to maintain optimal outcomes on stable therapy.
AYA Cancer Awareness Month offers an opportunity for nurses to go further in supporting AYAs with cancer.
The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.
Patients with myelofibrosis should reflect on their personal priorities and quality of life goals, understand the range of available JAK inhibitor treatment options, and openly communicate with their doctor to arrive at a shared decision for managing their disease.
It is essential to continue to develop and incorporate educational strategies to increase screening for colorectal cancer in our communities.
Discrepancies exist between actual patterns of care and recommendations based on clinical trials in adult patients with mantle cell lymphoma.
The addition of retifanlimab to chemotherapy increased progression-free survival in patients with advanced squamous cell carcinoma of the anal canal.
Tucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.
Experts discuss how, it is crucial to approach treatment strategies with both compassion and transparency. It is important to explain the complexity of the situation and maintain clear and accessible language when discussing treatment strategies with patients and their families.
Bispecific antibodies that engage T cells are an effective treatment modality in relapsed/refractory disease and are an important new treatment for relapsed large B-cell lymphoma.
Buying one for your practice or enhancing the one you have will help you cut costs and boost your financial stability.
Panelists discuss how emerging treatments, digital health tools, and enhanced care coordination could streamline disease management and improve quality of life while identifying opportunities to strengthen provider communication and access to resources.
Kristin M. Daly, MSN, ANP-BC, AOCNP, highlights the difference between somatic and germline variants.
The state-of-the-art facility represents the organization’s vision of global cancer care
Sharon Kauffman, PhD, RN, CNE, NPD-BC, OCN, provides an in-depth look at pirtobrutinib in a downloadable reference sheet.
The US Oncology Network (The Network) has developed one of the most comprehensive programs in the nation to support the professional development and retention of new oncology nurses.